90 research outputs found
„Einstellung“ als Vielfaktorenkategorie der Migrationsforschung
Diese religionssoziologische Arbeit untersucht Phänomene von Einstellungen, Einstellungswandel sowie Einflussfaktoren auf diesen unter den Umständen von Migration im Spannungsfeld historischer, sozialer, kultureller und politischer Einflüsse. Die Arbeit wurde angeregt durch die Entwicklung integrationspolitischer Ansätze am Anfang des 21. Jahrhunderts in Deutschland und die Situation der Zielgruppe von Menschen mit türkischem Migrationshintergrund dort. Aus Sicht der Religionswissenschaft zeigt sich die Thematik als ein interessantes Arbeitsfeld: In der öffentlichen Debatte um die Integration türkischstämmiger Personen in Deutschland spielt deren muslimische Religiosität eine maßgebliche Rolle. Die in der Debatte zum Teil sehr essentialistische Sicht auf Religion und Kultur wird in der Arbeit in Frage gestellt und die Bedeutung der Religion wird in Relation zu anderen strukturellen und kulturellen Faktoren betrachtet und somit in ihren gesellschaftlichen Kontext eingebettet
Brustkrebs: Auf dem Weg zu einer personalisierten Therapie : molekulare Subtypen und "Wirtsfaktoren" entscheiden ĂĽber Prognose und Therapie-Erfolg
Brustkrebs ist die häufigste Krebserkrankung und Todesursache bei Frauen. Die Forschung der letzten Jahrzehnte hat gezeigt, dass es sich dabei nicht um eine einzelne, immer gleich verlaufende Erkrankung handelt. Vielmehr geht man heute davon aus, dass Brustkrebs eine heterogene Erkrankung mit verschiedenen Subtypen darstellt. Sie lassen sich klinisch und molekular deutlich von einander unterscheiden. Wichtiges Ziel der modernen Forschung und ihrer Methoden ist daher die Entwicklung einer individuellen Therapie für jede einzelne Patientin
Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures
Background: Current prognostic gene signatures for breast cancer mainly reflect proliferation status and have limited value in triple-negative (TNBC) cancers. The identification of prognostic signatures from TNBC cohorts was limited in the past due to small sample sizes.
Methodology/Principal Findings: We assembled all currently publically available TNBC gene expression datasets generated on Affymetrix gene chips. Inter-laboratory variation was minimized by filtering methods for both samples and genes. Supervised analysis was performed to identify prognostic signatures from 394 cases which were subsequently tested on an independent validation cohort (n = 261 cases).
Conclusions/Significance: Using two distinct false discovery rate thresholds, 25% and <3.5%, a larger (n = 264 probesets) and a smaller (n = 26 probesets) prognostic gene sets were identified and used as prognostic predictors. Most of these genes were positively associated with poor prognosis and correlated to metagenes for inflammation and angiogenesis. No correlation to other previously published prognostic signatures (recurrence score, genomic grade index, 70-gene signature, wound response signature, 7-gene immune response module, stroma derived prognostic predictor, and a medullary like signature) was observed. In multivariate analyses in the validation cohort the two signatures showed hazard ratios of 4.03 (95% confidence interval [CI] 1.71–9.48; P = 0.001) and 4.08 (95% CI 1.79–9.28; P = 0.001), respectively. The 10-year event-free survival was 70% for the good risk and 20% for the high risk group. The 26-gene signatures had modest predictive value (AUC = 0.588) to predict response to neoadjuvant chemotherapy, however, the combination of a B-cell metagene with the prognostic signatures increased its response predictive value. We identified a 264-gene prognostic signature for TNBC which is unrelated to previously known prognostic signatures
ABC3 Consensus: Assessment by a German Group of Experts
The Advanced Breast Cancer Third International Consensus Conference on the diagnosis and treatment of advanced breast cancer took place in Lisbon, Portugal, on November 5-7, 2015. This year's conference (ABC3) was focused on the treatment of metastatic breast cancer (stage IV), as it was 4 years ago at the first consensus meeting (ABC1). A matter of particular interest was the patients' perspective. Thus, patient-relevant issues were addressed by the consensus discussions, such as those on treatment goals, quality of life, care of long-term survivors ('survivorship issues'), and coping with disease-related symptoms and the side effects of treatment. Further important issues on the agenda were the use of standardized instruments for the assessment of individual treatment success ('patient-reported outcome measures') and the evaluation of the benefit of novel drugs (e.g. the European Society for Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale). Diagnosis and treatment of inoperable locally advanced breast cancer had already been discussed 2 years earlier at the ABC2 Consensus and were not dealt with in the framework of this year's ABC3 Consensus. With regard to country-specific peculiarities, which unavoidably found their way into the ABC Consensus, a working group of German breast cancer experts commented on the voting results of the ABC panelists. As for the past consensus, the group specially considered the German guidelines for the diagnosis and treatment of breast cancer (AGO (Gyneco-Oncology Working Group), S3, DGHO (German Society of Hematology and Medical Oncology)) in order to adapt the ABC3 consensus for everyday therapy in Germany. (C) 2016 S. Karger GmbH, Freibur
Parturient perineal distensibility tolerance assessed by EPI-NO: an observational study
DMS triggers apoptosis associated with the inhibition of SPHK1/NF-ÎşB activation and increase in intracellular Ca2+ concentration in human cancer cells
N,N-Dimethyl-D-erythro-sphingosine (DMS) is known to induce cell apoptosis by specifically inhibiting sphingosine kinase 1 (SPHK1) and modulating the activity of cellular ceramide levels. The present study investigated the effects and the mechanism(s) of action of DMS in human lung cancer cells. We found that DMS dose-dependently suppressed cell proliferation and induced cell apoptosis in the human lung cancer cell line, A549. Mechanistically, treatment with DMS suppressed the activation of SPHK1 and nuclear factor-B (NF-B) p65, but increased intracellular [Ca2+]i in A549 cells. This study demonstrates that DMS triggers the apoptosis of human lung cancer cells through the modulation of SPHK1, NF-B and calcium signaling. These molecules may represent targets for anticancer drug design
Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus – Assessment by a German Group of Experts
The 5th International Consensus Conference for Advanced
Breast Cancer (ABC5) took place on November 14–16, 2019,
in Lisbon, Portugal. Its aim is to standardize the treatment of
advanced breast cancer based on the available evidence and
to ensure that all breast cancer patients worldwide receive
adequate treatment and access to new therapies. This year,
the conference focused on developments and study results
in the treatment of patients with hormone receptor-positive/HER2-negative breast cancer as well as precision medicine. As in previous years, patient advocates from around the
world were integrated into the ABC conference and had seats on the ABC consensus panel. In the present paper, a
working group of German breast cancer experts comments
on the results of the on-site ABC5 consensus votes by ABC
panelists regarding their applicability for routine treatment
in Germany. These comments take the recommendations of
the Breast Committee of the Gynecological Oncology Working Group (Arbeitsgemeinschaft Gynäkologische Onkologie;
AGO) into account. The report and assessment presented
here pertain to the preliminary results of the ABC5 consensus. The final version of the statements will be published in
Annals of Oncology and The Breast
Sphingosine kinase 2 deficiency increases proliferation and migration of renal mouse mesangial cells and fibroblasts
- …